Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells

Pharmacological Reports

Volumn 65, Issue 2, 2013, Pages 453-459

  Wu, Guo Sheng ^a   Lu, Jin Jian ^a,b   Guo, Jia Jie ^a   Huang, Ming Qing ^c   Gan, Li ^b   Chen, Xiu Ping ^a   Wang, Yi Tao ^a  

^a University of Macau   (Macao)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^c FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Anti tumor; Apoptosis; Dihydroartemisinin; Doxorubicin; MCF 7; Synergistic

Indexed keywords

CASPASE 7; CASPASE 9; DIHYDROARTEMISININ; DOXORUBICIN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL STRAIN MCF 7; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG ANTAGONISM; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84879352014     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71021-1     Document Type: Article

References (20)

1. Chen HH, Zhou HJ, Wang WQ, Wu GD: Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother Pharmacol, 2004, 53, 423-432.
2. Chou TC, Talalay P: Generalized equations for the analysis of inhibitions of Michaelis-Menten and higherorder kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem, 1981, 115, 207-216.
3. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul, 1984, 22, 27-55.
4. Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG et al.: Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol, 2003, 64, 382-394.
5. He Q, Shi J, Shen XL, An J, Sun H,Wang L, Hu YJ et al.: Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells. Cancer Biol Ther, 2010, 9, 819-824.
6. Hou J,Wang D, Zhang R,Wang H: Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res, 2008, 14, 5519-5530.
7. Hwang YP, Yun HJ, Kim HG, Han EH, Lee GW, Jeong HG: Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCa/Raf/MAPKs and NF-kB/AP-1-dependent mechanisms. Biochem Pharmacol, 2010, 79, 1714-1726.
8. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin, 2005, 55, 10-30.
9. Lu JJ, Chen SM, Ding J, Meng LH: Characterization of dihydroartemisinin- resistant colon carcinoma HCT116/R cell line. Mol Cell Biochem, 2012, 360, 329-337
10. Lu JJ, Chen SM, Zhang XW, Ding J, Meng LH: The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells. Invest New Drugs, 2011, 29, 1276-1283.
11. Lu JJ, Meng LH, Cai YJ, Chen Q, Tong LJ, Lin LP, Ding J: Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-Activated protein kinase activation but independent of reactive oxygen species. Cancer Biol Ther, 2008, 7, 1017-1023.
12. Lu JJ, Meng LH, Shankavaram UT, Zhu CH, Tong LJ, Chen G, Lin LP et al.: Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol, 2010, 80, 22-30.
13. Mercer AE, Maggs JL, Sun XM, Cohen GM, Chadwick J, O'Neill PM, Park BK: Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. J Biol Chem, 2007, 282, 9372-9382.
14. Riganti C, Doublier S, Viarisio D, Miraglia E, Pescarmona G, Ghigo D, Bosia A: Artemisinin induces doxorubicin resistance in human colon cancer cells via calciumdependent activation of HIF-1a and P-glycoprotein overexpression. Br J Pharmacol, 2009, 156, 1054-1066.
15. Salvioli S, Ardizzoni A, Franceschi C, Cossarizza A: JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess DY changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett, 1997, 411, 77-82.
16. Szliszka E, Czuba ZP, Sêdek , Paradysz A, Król W: Enhanced TRAIL-mediated apoptosis in prostate cancer cells by the bioactive compounds neobavaisoflavone and psoralidin isolated from Psoralea corylifolia. Pharmacol Rep, 2011, 63, 139-48.
17. Tan W, Lu J, Huang M, Li Y, Chen M, Wu G, Gong J et al.: Anti-cancer natural products isolated from chinese medicinal herbs. Chin Med, 6, 27.
18. White NJ: Qinghaosu (artemisinin): the price of success. Science, 2008, 320, 330-334.
19. Wonders KY, Reigle BS: Trastuzumab and doxorubicinrelated cardiotoxicity and the cardioprotective role of exercise. Integr Cancer Ther, 2009, 8, 17-21.
20. Zhu H, Ding WJ, Wu R, Weng QJ, Lou JS, Jin RJ, Lu W et al.: Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol. Cancer Invest, 2010, 28, 23-32.